The pharmacokinetics of a diclofenac sodium was investigated in swine. A single intravenous (i.v.) or intramuscular (i.m.) injection of 5% diclofenac sodium (concentration = 2.5 mg · kg-1) was administered to 8 healthy pigs according to a two-period crossover design. The pharmacokinetic parameters were calculated by non-compartmental analysis with DAS2.1.1 software. After a single i.v. administration, the main pharmacokinetic parameters of diclofenac sodium injection in swine were as follows: the elimination half-time (T1/2β) was 1.32±0.34 h; the area under the curve (AUC) was (55.50±5.50 μg · mL-1 h; the mean residence time (MRT) was 1.60±0.28 h; the apparent volume of distribution (Vd) was 0.50±0.05 L · kg-1; and the body clearance (CLB) was 0.26±0.04 L · (h · kg)-1. After the single i.m. administration, the pharmacokinetic parameters were as follows: peak time (Tmax) was 1.19±0.26 h; and peak concentration (Cmax) was 11.61±5.99 μg mL-1. The diclofenac sodium has the following pharmacokinetic characteristics in swine: rapid absorption and elimination; high peak concentration; and bioavailability.
Nano-sized yttria (Y2O3) powders were synthesized by a polymer solution route using polyvinyl alcohol (PVA) as an organic carrier. The PVA polymer affected the dispersion of yttrium ions in precursor sol. In this study, three kinds of PVA polymer (different molecular weight) were applied for synthesis of yttria powder. The PVA type as well as calcination temperature had a strongly influence on the particle morphology. Single crystal nano wire particles were observed at the temperature of polymer burn out range and the size was dependent on the PVA type. The stable, fully crystallized yttria powder was obtained through the calcination at 800°C for 1 h. The yttria powder prepared with the high weight PVA (MW: 153,000) revealed a particle size of 30 nm with a surface area of 18.8 m2/g.
U-type ferrite typified by Ba4Co2Fe36O60 is used as a RAM (Radar Absorbing Materials) in the X-band (8-12 GHz). Ba4Co2Fe36O60 is known to have a complex crystal structure, which makes it difficult to obtain single phase and have low reproducibility. Previously known U-type ferrites have been fabricated based on a ceramic process that mixing (by a ball mill), calcining, grinding, binder mixing, drying, sieving, pressing and sintering. In contrast, the process of preparing the powder by the sol-gel method and its heat-treating is advantageous in that it can reduce the process steps and the required time. In addition, the precise stoichiometric control by the sol-gel method can effectively evaluate the effect of added or substituted elements. In this study investigates the crystal structure of Ba4Co2Fe36O60 synthesized by the sol-gel method and the morphology of U-type ferrite nano-powders according to various heat treatment conditions. Analysis of the crystal structure is used for XRD. Morphology and size are observed by SEM. In addition, VSM is performed to confirm the change of magnetic properties according to various heat treatment conditions.
As-cast Mg-6Li-0.3Zn-0.6Y and Mg-6Li-1.2Zn-1.2Y (wt%) alloys were prepared and extruded at 260 oC with an extrusion ratio of 25. The microstructure and mechanical behavior of as-cast and extruded alloys are reported and discussed. The results show that Mg-6Li-1.2Zn- 1.2Y alloy is composed of α-Mg, β-Li, and W-Mg3Zn3Y2 phases while Mg-6Li-0.3Zn-0.6Y alloy contains α-Mg, β-Li, W-Mg3Zn3Y2 phase and X-Mg12ZnY. After hot extrusion, the microstructure of specimens is refined and the average grains size of extruded alloys is 15 μm. Dynamic recrystallization occurs during the extrusion, leading to grain refinement of test alloys. Both the strength and elongation of test alloys are improved by extrusion. The extruded Mg-6Li-0.3Zn-0.6Y alloy possesses an ultimate strength of 225 MPa with an elongation of 18% while the strength and elongation of Mg-6Li-1.2Zn-1.2Y alloy are 206 MPa and 28%, respectively. The X-phase in Mg-6Li-0.3Zn- 0.6Y is beneficial to the improvement of strength, but will lead to the decrease of ductility.
In order to compare the pathogenicity of different Tembusu virus (TMUV) strains from geese, ducks and chickens, 56 5-day-old Cherry Valley ducklings which were divided into 7 groups and infected intramuscularly with 7´105 PFU/ml per duck of six challenge virus stocks. The clinical signs, weight gain, mortality, macroscopic and microscopic lesions, virus loads in sera of 1, 3, 5, 7, 11 and 14 dpi and serum antibody titers were examined. The results showed that these viruses could make the young ducks sick, but the clinical signs differed with the different species-original strains. All the experimental groups lose markedly in weight gain compared to the control, but there were no obvious distinctions in weight gains, as well as macroscopic and microscopic lesions of dead ducks between the infected groups. However, the groups of waterfowl-derived strains (from geese and ducks) showed more serious clinical signs and higher relative expressions of virus loads in sera than those from chicken-derived. The mortality of waterfowl groups was 37.5%, and the greatest mortality of chicken groups was 12.5%. The serum antibodies of the geese-species group JS804 appeared earlier and were higher in the titers than others. Taken toghter, the pathogenicity of waterfowl-derived TMUV was more serious than chicken-derived TMUV and JS804 could be chosen as one TMUV vaccine strain to protect from the infection.